TGF-β/Smad Signaling in Kidney Disease

Seminars in Nephrology

Volumn 32, Issue 3, 2012, Pages 236-243

  Lan, Hui Y ^a   Chung, Arthur C K ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Chronic kidney disease; Renal fibrosis; Renal inflammation; TGF Smad signaling

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MICRORNA; MICRORNA 21; MICRORNA 29B; MITOGEN ACTIVATED PROTEIN KINASE; SMAD2 PROTEIN; SMAD3 PROTEIN; SMAD7 PROTEIN; TRANSFORMING GROWTH FACTOR BETA1;

ARTICLE; CHRONIC KIDNEY DISEASE; DRUG TARGETING; EPITHELIAL MESENCHYMAL TRANSITION; HUMAN; INTRACELLULAR SIGNALING; KIDNEY FIBROSIS; KIDNEY INJURY; KIDNEY TUBULE EPITHELIUM; MOLECULAR BIOLOGY; MYOFIBROBLAST; NEPHRITIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; REGULATORY MECHANISM; VIRAL GENE DELIVERY SYSTEM;

EID: 84864148484     PISSN: 02709295     EISSN: 15584488     Source Type: Journal    
DOI: 10.1016/j.semnephrol.2012.04.002     Document Type: Article

References (75)

1. Bottinger E.P. TGF-beta in renal injury and disease. Semin Nephrol 2007, 27:309-320.
2. Lan H.Y. Smad7 as a therapeutic agent for chronic kidney diseases. Front Biosci 2008, 13:4984-4992.
3. Wang W., Koka V., Lan H.Y. Transforming growth factor-beta and Smad signalling in kidney diseases. Nephrology (Carlton) 2005, 10:48-56.
4. Roberts A.B. Molecular and cell biology of TGF-beta. Miner Electrolyte Metab 1998, 24:111-119.
5. Lan H.Y. Tubular epithelial-myofibroblast transdifferentiation mechanisms in proximal tubule cells. Curr Opin Nephrol Hypertens 2003, 12:25-29.
6. Border W.A., Noble N.A. Evidence that TGF-beta should be a therapeutic target in diabetic nephropathy. Kidney Int 1998, 54:1390-1391.
7. Kopp J.B., Factor V.M., Mozes M., Nagy P., Sanderson N., Bottinger E.P., et al. Transgenic mice with increased plasma levels of TGF-beta 1 develop progressive renal disease. Lab Invest 1996, 74:991-1003.
8. Sanderson N., Factor V., Nagy P., Kopp J., Kondaiah P., Wakefield L., et al. Hepatic expression of mature transforming growth factor beta 1 in transgenic mice results in multiple tissue lesions. Proc Natl Acad Sci U S A 1995, 92:2572-2576.
9. Letterio J.J., Roberts A.B. Regulation of immune responses by TGF-beta. Annu Rev Immunol 1998, 16:137-161.
10. Yaswen L., Kulkarni A.B., Fredrickson T., Mittleman B., Schiffman R., Payne S., et al. Autoimmune manifestations in the transforming growth factor-beta 1 knockout mouse. Blood 1996, 87:1439-1445.
11. Li M.O., Wan Y.Y., Flavell R.A. T cell-produced transforming growth factor-beta1 controls T cell tolerance and regulates Th1- and Th17-cell differentiation. Immunity 2007, 26:579-591.
12. Li M.O., Sanjabi S., Flavell R.A. Transforming growth factor-beta controls development, homeostasis, and tolerance of T cells by regulatory T cell-dependent and -independent mechanisms. Immunity 2006, 25:455-471.
13. Chernajovsky Y., Adams G., Triantaphyllopoulos K., Ledda M.F., Podhajcer O.L. Pathogenic lymphoid cells engineered to express TGF beta 1 ameliorate disease in a collagen-induced arthritis model. Gene Ther 1997, 4:553-559.
14. Subra J.F., Cautain B., Xystrakis E., Mas M., Lagrange D., van der Heijden H., et al. The balance between CD45RChigh and CD45RClow CD4 T cells in rats is intrinsic to bone marrow-derived cells and is genetically controlled. J Immunol 2001, 166:2944-2952.
15. Fuss I.J., Boirivant M., Lacy B., Strober W. The interrelated roles of TGF-beta and IL-10 in the regulation of experimental colitis. J Immunol 2002, 168:900-908.
16. Hansen G., McIntire J.J., Yeung V.P., Berry G., Thorbecke G.J., Chen L., et al. CD4(+) T helper cells engineered to produce latent TGF-beta1 reverse allergen-induced airway hyperreactivity and inflammation. J Clin Invest 2000, 105:61-70.
17. Thorbecke G.J., Umetsu D.T., deKruyff R.H., Hansen G., Chen L.Z., Hochwald G.M. When engineered to produce latent TGF-beta1, antigen specific T cells down regulate Th1 cell-mediated autoimmune and Th2 cell-mediated allergic inflammatory processes. Cytokine Growth Factor Rev 2000, 11:89-96.
18. Oida T., Zhang X., Goto M., Hachimura S., Totsuka M., Kaminogawa S., et al. CD4+CD25- T cells that express latency-associated peptide on the surface suppress CD4+CD45RBhigh-induced colitis by a TGF-beta-dependent mechanism. J Immunol 2003, 170:2516-2522.
19. Schnaper H.W., Hayashida T., Poncelet A.C. It's a Smad world: regulation of TGF-beta signaling in the kidney. J Am Soc Nephrol 2002, 13:1126-1128.
20. Li J.H., Huang X.R., Zhu H.J., Oldfield M., Cooper M., Truong L.D., et al. Advanced glycation end products activate Smad signaling via TGF-beta-dependent and independent mechanisms: implications for diabetic renal and vascular disease. FASEB J 2004, 18:176-178.
21. Chung A.C., Zhang H., Kong Y.Z., Tan J.J., Huang X.R., Kopp J.B., et al. Advanced glycation end-products induce tubular CTGF via TGF-beta-independent Smad3 signaling. J Am Soc Nephrol 2010, 21:249-260.
22. Lan H.Y., Mu W., Tomita N., Huang X.R., Li J.H., Zhu H.J., et al. Inhibition of renal fibrosis by gene transfer of inducible Smad7 using ultrasound-microbubble system in rat UUO model. J Am Soc Nephrol 2003, 14:1535-1548.
23. Terada Y., Hanada S., Nakao A., Kuwahara M., Sasaki S., Marumo F. Gene transfer of Smad7 using electroporation of adenovirus prevents renal fibrosis in post-obstructed kidney. Kidney Int 2002, 61:94-98.
24. Hou C.C., Wang W., Huang X.R., Fu P., Chen T.H., Sheikh-Hamad D., et al. Ultrasound-microbubble-mediated gene transfer of inducible Smad7 blocks transforming growth factor-beta signaling and fibrosis in rat remnant kidney. Am J Pathol 2005, 166:761-771.
25. Wang W., Huang X.R., Canlas E., Oka K., Truong L.D., Deng C., et al. Essential role of Smad3 in angiotensin II-induced vascular fibrosis. Circ Res 2006, 98:1032-1039.
26. Verrecchia F., Chu M.L., Mauviel A. Identification of novel TGF-beta/Smad gene targets in dermal fibroblasts using a combined cDNA microarray/promoter transactivation approach. J Biol Chem 2001, 276:17058-17062.
27. Sato M., Muragaki Y., Saika S., Roberts A.B., Ooshima A. Targeted disruption of TGF-beta1/Smad3 signaling protects against renal tubulointerstitial fibrosis induced by unilateral ureteral obstruction. J Clin Invest 2003, 112:1486-1494.
28. Flanders K.C., Sullivan C.D., Fujii M., Sowers A., Anzano M.A., Arabshahi A., et al. Mice lacking Smad3 are protected against cutaneous injury induced by ionizing radiation. Am J Pathol 2002, 160:1057-1068.
29. Bonniaud P., Kolb M., Galt T., Robertson J., Robbins C., Stampfli M., et al. Smad3 null mice develop airspace enlargement and are resistant to TGF-beta-mediated pulmonary fibrosis. J Immunol 2004, 173:2099-2108.
30. Fujimoto M., Maezawa Y., Yokote K., Joh K., Kobayashi K., Kawamura H., et al. Mice lacking Smad3 are protected against streptozotocin-induced diabetic glomerulopathy. Biochem Biophys Res Commun 2003, 305:1002-1007.
31. Isono M., Chen S., Hong S.W., Iglesias-de la Cruz M.C., Ziyadeh F.N. Smad pathway is activated in the diabetic mouse kidney and Smad3 mediates TGF-beta-induced fibronectin in mesangial cells. Biochem Biophys Res Commun 2002, 296:1356-1365.
32. Zhou Y., Mao H., Li S., Cao S., Li Z., Zhuang S., et al. HSP72 inhibits Smad3 activation and nuclear translocation in renal epithelial-to-mesenchymal transition. J Am Soc Nephrol 2010, 21:598-609.
33. Li J., Qu X., Yao J., Caruana G., Ricardo S.D., Yamamoto Y., et al. Blockade of endothelial-mesenchymal transition by a Smad3 inhibitor delays the early development of streptozotocin-induced diabetic nephropathy. Diabetes 2010, 59:2612-2624.
34. Meng X.M., Huang X.R., Chung A.C., Qin W., Shao X., Igarashi P., et al. Smad2 Protects against TGF-{beta}/Smad3-Mediated Renal Fibrosis. J Am Soc Nephrol 2010, 21:1477-1487.
35. Yang F., Chung A.C., Huang X.R., Lan H.Y. Angiotensin II induces connective tissue growth factor and collagen I expression via transforming growth factor-beta-dependent and -independent Smad pathways: the role of Smad3. Hypertension 2009, 54:877-884.
36. Zhou L., Fu P., Huang X.R., Liu F., Chung A.C., Lai K.N., et al. Mechanism of chronic aristolochic acid nephropathy: role of Smad3. Am J Physiol Renal Physiol 2010, 298:F1006-F1017.
37. Afrakhte M., Moren A., Jossan S., Itoh S., Sampath K., Westermark B., et al. Induction of inhibitory Smad6 and Smad7 mRNA by TGF-beta family members. Biochem Biophys Res Commun 1998, 249:505-511.
38. Zhu H.J., Iaria J., Sizeland A.M. Smad7 differentially regulates transforming growth factor beta-mediated signaling pathways. J Biol Chem 1999, 274:32258-32264.
39. Kavsak P., Rasmussen R.K., Causing C.G., Bonni S., Zhu H., Thomsen G.H., et al. Smad7 binds to Smurf2 to form an E3 ubiquitin ligase that targets the TGF beta receptor for degradation. Mol Cell 2000, 6:1365-1375.
40. Ebisawa T., Fukuchi M., Murakami G., Chiba T., Tanaka K., Imamura T., et al. Smurf1 interacts with transforming growth factor-beta type I receptor through Smad7 and induces receptor degradation. J Biol Chem 2001, 276:12477-12480.
41. Uchida K., Nitta K., Kobayashi H., Kawachi H., Shimizu F., Yumura W., et al. Localization of Smad6 and Smad7 in the rat kidney and their regulated expression in the anti-Thy-1 nephritis. Mol Cell Biol Res Commun 2000, 4:98-105.
42. Fukasawa H., Yamamoto T., Togawa A., Ohashi N., Fujigaki Y., Oda T., et al. Down-regulation of Smad7 expression by ubiquitin-dependent degradation contributes to renal fibrosis in obstructive nephropathy in mice. Proc Natl Acad Sci U S A 2004, 101:8687-8692.
43. Ka S.M., Huang X.R., Lan H.Y., Tsai P.Y., Yang S.M., Shui H.A., et al. Smad7 gene therapy ameliorates an autoimmune crescentic glomerulonephritis in mice. J Am Soc Nephrol 2007, 18:1777-1788.
44. Chung A.C., Huang X.R., Zhou L., Heuchel R., Lai K.N., Lan H.Y. Disruption of the Smad7 gene promotes renal fibrosis and inflammation in unilateral ureteral obstruction (UUO) in mice. Nephrol Dial Transplant 2009, 24:1443-1454.
45. Chen H., Huang X.R., Wang W., Li J., Heuchel R.L., Chung A.C., et al. The protective role of Smad7 in diabetic kidney disease: mechanism and therapeutic potential. Diabetes 2010, 60:590-601.
46. Li J.H., Zhu H.J., Huang X.R., Lai K.N., Johnson R.J., Lan H.Y. Smad7 inhibits fibrotic effect of TGF-Beta on renal tubular epithelial cells by blocking Smad2 activation. J Am Soc Nephrol 2002, 13:1464-1472.
47. Yang F., Huang X.R., Chung A.C., Hou C.C., Lai K.N., Lan H.Y. Essential role for Smad3 in angiotensin II-induced tubular epithelial-mesenchymal transition. J Pathol 2010, 221:390-401.
48. Inoue Y., Imamura T. Regulation of TGF-beta family signaling by E3 ubiquitin ligases. Cancer Sci 2008, 99:2107-2112.
49. Wang W., Huang X.R., Li A.G., Liu F., Li J.H., Truong L.D., et al. Signaling mechanism of TGF-beta1 in prevention of renal inflammation: role of Smad7. J Am Soc Nephrol 2005, 16:1371-1383.
50. Kanamaru Y., Nakao A., Mamura M., Suzuki Y., Shirato I., Okumura K., et al. Blockade of TGF-beta signaling in T cells prevents the development of experimental glomerulonephritis. J Immunol 2001, 166:2818-2823.
51. Ng Y.Y., Hou C.C., Wang W., Huang X.R., Lan H.Y. Blockade of NFkappaB activation and renal inflammation by ultrasound-mediated gene transfer of Smad7 in rat remnant kidney. Kidney Int Suppl 2005, 94:S83-S91.
52. Huang X.R., Chung A.C., Wang X.J., Lai K.N., Lan H.Y. Mice overexpressing latent TGF-beta1 are protected against renal fibrosis in obstructive kidney disease. Am J Physiol Renal Physiol 2008, 295:F118-F127.
53. Huang X.R., Chung A.C., Zhou L., Wang X.J., Lan H.Y. Latent TGF-beta1 protects against crescentic glomerulonephritis. J Am Soc Nephrol 2008, 19:233-242.
54. Simonsson M., Heldin C.H., Ericsson J., Gronroos E. The balance between acetylation and deacetylation controls Smad7 stability. J Biol Chem 2005, 280:21797-21803.
55. Jin Y.H., Jeon E.J., Li Q.L., Lee Y.H., Choi J.K., Kim W.J., et al. Transforming growth factor-beta stimulates p300-dependent RUNX3 acetylation, which inhibits ubiquitination-mediated degradation. J Biol Chem 2004, 279:29409-29417.
56. Stockis J., Colau D., Coulie P.G., Lucas S. Membrane protein GARP is a receptor for latent TGF-beta on the surface of activated human Treg. Eur J Immunol 2009, 39:3315-3322.
57. Wang R., Kozhaya L., Mercer F., Khaitan A., Fujii H., Unutmaz D. Expression of GARP selectively identifies activated human FOXP3+ regulatory T cells. Proc Natl Acad Sci U S A 2009, 106:13439-13444.
58. Derynck R., Zhang Y.E. Smad-dependent and Smad-independent pathways in TGF-beta family signalling. Nature 2003, 425:577-584.
59. Rodriguez-Vita J., Sanchez-Lopez E., Esteban V., Ruperez M., Egido J., Ruiz-Ortega M. Angiotensin II activates the Smad pathway in vascular smooth muscle cells by a transforming growth factor-beta-independent mechanism. Circulation 2005, 111:2509-2517.
60. Tian Z., Greene A.S., Pietrusz J.L., Matus I.R., Liang M. MicroRNA-target pairs in the rat kidney identified by microRNA microarray, proteomic, and bioinformatic analysis. Genome Res 2008, 18:404-411.
61. Zhong X., Chung A.C.K., Chen H., Meng X., Lan H.Y. TGF-beta-induced miR-21 mediated by Smad3, not Smad2, as a "potential" therapeutic target for renal fibrosis. J Am Soc Nephrol 2011, 22:1668-1681.
62. Qin W., Chung A.C.K., Huang X.R., Meng X.M., Hui D.S.C., Yu C.M., et al. miR-29 is negatively regulated by TGF-β via Smad3 signaling and inhibits fibrosis in vitro and in vivo. J Am Soc Nephrol 2011, 22:1462-1474.
63. Zhou Q., Fan J., Ding X., Peng W., Yu X., Chen Y., et al. TGF-{beta}-induced MiR-491-5p expression promotes Par-3 degradation in rat proximal tubular epithelial cells. J Biol Chem 2010, 285:40019-40027.
64. Kato M., Zhang J., Wang M., Lanting L., Yuan H., Rossi J.J., et al. MicroRNA-192 in diabetic kidney glomeruli and its function in TGF-beta-induced collagen expression via inhibition of E-box repressors. Proc Natl Acad Sci U S A 2007, 104:3432-3437.
65. Chung A.C., Huang X.R., Meng X., Lan H.Y. miR-192 mediates TGF-beta/Smad3-driven renal fibrosis. J Am Soc Nephrol 2010, 21:1317-1325.
66. Wang Q., Wang Y., Minto A.W., Wang J., Shi Q., Li X., et al. MicroRNA-377 is up-regulated and can lead to increased fibronectin production in diabetic nephropathy. FASEB J 2008, 22:4126-4135.
67. Park S.M., Gaur A.B., Lengyel E., Peter M.E. The miR-200 family determines the epithelial phenotype of cancer cells by targeting the E-cadherin repressors ZEB1 and ZEB2. Genes Dev 2008, 22:894-907.
68. Kriegel A.J., Fang Y., Liu Y., Tian Z., Mladinov D., Matus I.R., et al. MicroRNA-target pairs in human renal epithelial cells treated with transforming growth factor beta 1: a novel role of miR-382. Nucleic Acids Res 2010, 38:8338-8347.
69. Wang Q., Wang Y., Minto A.W., Wang J., Shi Q., Li X., et al. MicroRNA-377 is up-regulated and can lead to increased fibronectin production in diabetic nephropathy. FASEB J 2008, 22:4126-4135.
70. Du B., Ma L.M., Huang M.B., Zhou H., Huang H.L., Shao P., et al. High glucose down-regulates miR-29a to increase collagen IV production in HK-2 cells. FEBS Lett 2010, 584:811-816.
71. Wang B., Koh P., Winbanks C., Coughlan M.T., McClelland A., Watson A., et al. miR-200a prevents renal fibrogenesis through repression of TGF-{beta}2 expression. Diabetes 2010, 60:280-287.
72. Hill C., Flyvbjerg A., Rasch R., Bak M., Logan A. Transforming growth factor-beta2 antibody attenuates fibrosis in the experimental diabetic rat kidney. J Endocrinol 2001, 170:647-651.
73. Russo L.M., del Re E., Brown D., Lin H.Y. Evidence for a role of transforming growth factor (TGF)-beta1 in the induction of postglomerular albuminuria in diabetic nephropathy: amelioration by soluble TGF-beta type II receptor. Diabetes 2007, 56:380-388.
74. Petersen M., Thorikay M., Deckers M., van Dinther M., Grygielko E.T., Gellibert F., et al. Oral administration of GW788388, an inhibitor of TGF-beta type I and II receptor kinases, decreases renal fibrosis. Kidney Int 2008, 73:705-715.
75. Moon J.A., Kim H.T., Cho I.S., Sheen Y.Y., Kim D.K. IN-1130, a novel transforming growth factor-beta type I receptor kinase (ALK5) inhibitor, suppresses renal fibrosis in obstructive nephropathy. Kidney Int 2006, 70:1234-1243.